In July 2026, Nemera’s pen injector platform verified with SCHOTT Pharma’s cartriQ 3 mL ready-to-use glass cartridge system compatibility testing confirms easy-to-use and reliable integration of the delivery device and primary packaging, to ensure optimal device performance and patient safety. The partnership is also catering to the growing demands of the healthcare industry for patient-centric injectable therapies in home care settings.
The main aim of the partnership between Nemera, a world-leading provider of drug delivery device solutions and combination product services, and SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, is to support the shift of the healthcare industry from hospitals to home care settings for the convenience of patients. It has also helped to strengthen their business to provide pharmaceutical companies with a reliable, fully verified platform for injectable therapies.
“As healthcare increasingly moves closer to patients, pharmaceutical companies need to combine drug containment and delivery from the outset,” says Christian Mias, CEO of SCHOTT Pharma. “Together with Nemera, we are helping them address this growing demand through a proven and compatible platform solution.”
“Our collaboration with SCHOTT Pharma reflects our commitment to providing integrated drug delivery solutions that help simplify development and accelerate time to market”, says Marc Hämel, CEO of Nemera. “At Nemera, we believe that strong partnerships are essential to helping pharmaceutical companies bring combination products to patients more efficiently.”
As therapeutic combination products require seamless integration between the delivery device and the pharmaceutical primary packaging system, Nemera’s and SCHOTT Pharma’s partnership supports optimal product performance as well as patient safety and comfort.
Nemera has been a part of the healthcare industry for more than two decades now. It is a highly experienced company manufacturing pen injectors and autoinjectors in high volumes. It also offers a comprehensive portfolio of proprietary pen injector platforms developed with full intellectual property ownership. The huge platform addresses multiple healthcare-related issues, such as prescription therapies and diverse patient needs, which is manufactured in Nemera’s state-of-the-art facilities using advanced automation technologies.
On the other hand, SCHOTT Pharma’s cartriQ ready-to-use (RTU) glass cartridge system, manufactured from FIOLAX® Type I borosilicate glass with controlled hydrolytic resistance, is specifically designed to meet the demanding requirements of pen injectors, autoinjectors, and pump systems. Its features, such as its robust mechanical resistance, excellent cosmetic quality, and tight dimensional tolerances, help to support precise processing and reliable device functionality. Quality is ensured through 100% camera-controlled inspection, while geometric tolerances exceed ISO 13926-1 standards and can be further tightened for highly demanding applications.
The precisely controlled inner and outer diameters of the cartridge help to improve the manufacturing robustness, enhance visual inspection performance, and improve dose accuracy. Such characteristics also help to minimize overflow losses in multidose applications. Along with advanced defect detection capabilities, support cartridge integrity, sterility, and overall product quality.
A comprehensive study was conducted by Nemera’s laboratory in Poland on the mechanical and chemical performance of 3 mL cartriQ RTU cartridges. The main parameters of the study were based on critical performance, inclusive of break-loose and gliding forces (BLGF) as well as organic and inorganic leachable profiles, following accelerated aging conditions. Testing was performed in accordance with recognized industry standards, including ISO 21881 and ICH Q3D guidelines.
To assess the compatibility ahead, various other assessments covering dimensional accuracy, filling volume performance, air-bubble evaluation, and density measurements were also conducted. SCHOTT Pharma’s glass cartridge system met the criteria successfully, along with the predefined acceptance criteria. The results clearly declared excellent compatibility with Nemera’s pen injector platforms and provided high confidence in the combined solution. The results also declared full technical compatibility between the respective products from Nemara and SCHOTT Pharma. Hence, it also aids pharmaceutical companies with a commercially available, verified integrated solution that accelerates development timelines while mitigating technical risks associated with combination products.
The partnership of well-renowned healthcare companies is committed to supporting pharmaceutical partners with high-quality, reliable solutions for injectable drug delivery. It helps them to provide patient access to treatments that are safe, effective, and easy to use.
Nemara is known as a world-leading provider of drug delivery device solutions and combination product services. The main motto of putting patients first motivates them to design and manufacture devices to maximize treatment efficacy. They are also committed to an early device strategy and state-of-the-art manufacturing. Their main aim also includes providing the highest quality standards for their customers.
SCHOTT Pharma designs containment solutions that are grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The well-renowned healthcare company’s portfolio comprises drug containment solutions and delivery systems for injectable drugs, ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health.
31 July 2026
30 July 2026
30 July 2026
30 July 2026